Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced that positive initial data from the
ongoing, open label Phase II clinical trial of its investigational drug
PB272 (neratinib) for the treatment of patients with non-small cell lung
cancer (NSCLC) with HER2 mutations was presented today as a
late-breaking oral presentation at the European Society for Medical
Oncology (ESMO) 2014 Congress, taking place in Madrid, Spain.
for Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer investment picks